Objective: Anxiety disorders are common and often disabling. The goal of this study was to examine the genetic architecture of anxiety disorders and anxiety symptoms, which are also frequently comorbid with other mental disorders, such as major depressive disorder.
Methods: Using one of the world’s largest biobanks including genetic, environmental, and medical information, the Million Veteran Program, the authors performed a genome-wide association study of a continuous trait for anxiety (based on score on the Generalized Anxiety Disorder 2-item scale, N=199,611) as the primary analysis and self-report of physician diagnosis of anxiety disorder (N=224,330) as a secondary analysis.
This activity is only available to AJP CME subscribers.
Don't have a subscription to AJP CME? Subscribe Now!
- AJP Subscriber – 12 Month CME Subscription: $155.00
- Non AJP Subscriber – 12 Month CME Subscription: $310.00
If you have questions about AJP CME subscriptions, please contact firstname.lastname@example.org.
The participant will classify particular genome-wide signals that have a significant relationship with anxiety traits.
This program is designed for all psychiatrists in clinical practice, residents in Graduate Medical Education programs, medical students interested in psychiatry, and other physicians who wish to advance their current knowledge of clinical medicine.
Duration: 1 hour
Begin Date: March 1, 2020
End Date: February 28, 2022
In order to earn CME credit, subscribers should read through the material presented in the article. After reading the article, complete the quiz and submit your evaluation and study hours (up to 1 AMA PRA Category 1 Credit™). A score of 60% or higher is required to receive credit.
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The APA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity
Title: Reproducible Genetic Risk Loci for Anxiety: Results From ∼200,000 Participants in the Million Veteran Program
Authors: Daniel F. Levey, Ph.D., Joel Gelernter, M.D., Renato Polimanti, Ph.D., Hang Zhou, Ph.D., Zhongshan Cheng, Ph.D., Mihaela Aslan, Ph.D., Rachel Quaden, M.A., John Concato, M.D., M.P.H., Krishnan Radhakrishnan, M.D., Ph.D., Julien Bryois, Ph.D., Patrick F. Sullivan, M.D., the Million Veteran Program, Murray B. Stein, M.D., M.P.H.
Affiliations: Division of Human Genetics, Department of Psychiatry, Yale University School of Medicine, New Haven, Conn., and Department of Psychiatry, Veterans Affairs Connecticut Healthcare Center, West Haven, Conn. (D.F.L., J.G., R.P., H.Z., Z.C.); VA Clinical Epidemiology Research Center, VA Connecticut Healthcare System, West Haven, Conn. (M.A., J.C., K.R.); Department of Medicine, Yale University School of Medicine, New Haven, Conn. (M.A., J.C.); Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System, Boston (R.Q.); College of Medicine, University of Kentucky, Lexington (K.R.); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm (J.B., P.F.S.); Departments of Genetics and Psychiatry, University of North Carolina, Chapel Hill (P.F.S.); Psychiatry Service, VA San Diego Healthcare System, San Diego, and Departments of Psychiatry and of Family Medicine and Public Health, University of California San Diego, La Jolla (M.B.S.).
Disclosures: Dr. Sullivan has served on an advisory committee and received grant support from Lundbeck and served on a scientific advisory board for Pfizer. Dr. Gelernter is named as co-inventor on PCT patent application 15/878,640 (genotype-guided dosing of opioid agonists), filed January 24, 2018. Dr. Stein has served as a consultant for Aptinyx, Bionomics, Janssen, Jazz Pharmaceuticals, Neurocrine, Pfizer, and Oxeia Biopharmaceuticals. The other authors report no financial relationships with commercial interests.
Discussion of unapproved or investigational use of products*: No.
*APA policy requires disclosure by CME authors of unapproved or investigational use of products discussed in CME programs. Off-label use of medications by individual physicians is permitted and common. Decisions about off-label use can be guided by scientific literature and clinical experience.
Ned H. Kalin, M.D. (Editor-in-Chief, AJP); Carolyn Rodriguez, M.D., Ph.D. (Deputy Editor, AJP); Michael D. Roy (Editorial Director, AJP); Michael A. Pogachar (Online Content Manager, Journals). Dr. Kalin has served as a consultant to the Board of Scientific Advisors, the Pritzker Neuropsychiatric Disorders Research Consortium, and the Skyland Trail Advisory Board and as Councilor, Society of Biological Psychiatry. Dr. Rodriguez has served as a consultant to Allergan, Blackthorn, Epiodyne, and Rugen. Mr. Roy and Mr. Pogachar report no financial relationships with commercial interests.
Optimal System Configuration:
- Flash Player: Adobe Flash Player 10.1+
- Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+
- Operating System: Windows XP+ or Mac OS X 10.4+
- Internet Connection: 1 Mbps or higher
- Screen Resolution: 1024 x 768 pixels.
- Windows PC:500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
- Macintosh: Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit
For assistance: Contact email@example.com for questions about this course | Contact firstname.lastname@example.org for technical assistance